HomeGMAB • NASDAQ
add
Genmab A/S - ADR
Previous close
$29.98
Day range
$29.63 - $30.01
Year range
$26.32 - $42.72
Market cap
19.47B USD
Avg Volume
489.81K
In the news
Financials
Income Statement
Revenue
Net income
(DKK) | Mar 2024info | Y/Y change |
---|---|---|
Revenue | 4.14B | 45.16% |
Operating expense | 3.16B | 30.62% |
Net income | 1.32B | 486.28% |
Net profit margin | 31.98 | 303.79% |
Earnings per share | 20.18 | 39,820.87% |
EBITDA | 861.00M | 66.22% |
Effective tax rate | 22.79% | — |
Balance Sheet
Total assets
Total liabilities
(DKK) | Mar 2024info | Y/Y change |
---|---|---|
Cash and short-term investments | 29.58B | 20.53% |
Total assets | 36.68B | 20.68% |
Total liabilities | 4.18B | 30.56% |
Total equity | 32.50B | — |
Shares outstanding | 65.14M | — |
Price to book | 0.06 | — |
Return on assets | 5.56% | — |
Return on capital | 6.08% | — |
Cash Flow
Net change in cash
(DKK) | Mar 2024info | Y/Y change |
---|---|---|
Net income | 1.32B | 486.28% |
Cash from operations | 1.51B | -53.23% |
Cash from investing | -1.44B | -10,984.62% |
Cash from financing | -595.00M | 2.62% |
Net change in cash | -197.00M | -108.23% |
Free cash flow | 1.15B | -58.69% |
About
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, USA, and Genmab K.K. in Tokyo, Japan. Genmab is a dual-listed company with shares traded on both the Copenhagen Stock Exchange in Denmark and the NASDAQ Global Select Market in the US. Wikipedia
Founded
Feb 1999
Website
Employees
2,286